Lomax is generally considered relevant for addressing bacterial infections that cause acute symptomatic distress across specific physiological systems. It is commonly used in contexts where supportive symptom management is appropriate.

Targeting Acute Infections of the Urinary and Respiratory Tracts

Lomax is commonly used to help address bacterial infections that cause acute symptomatic distress in the genitourinary and lower respiratory systems. It is generally applied across conditions that present with disruptive symptom manifestations, such as the painful urination of cystitis or the intensified cough and sputum of an acute bronchitis exacerbation, contributing to easing the overall symptom load.

Managing Localized Ocular and Preventative Needs

The medication is relevant in clinical settings marked by the heightened discomfort of localized eye infections, such as bacterial conjunctivitis, where it is used for managing symptom clusters like discharge and irritation. The medication is also applied in preventative contexts in specific clinical scenarios, often used before certain procedures, and supports general well-being during symptomatic phases.

---

Quick Fact: Relief for Disruptive Symptoms
This medication is commonly used to help manage symptoms linked to organ-specific functional stress, such as painful urination or purulent ocular discharge, assisting with maintaining functional stability.

Regulatory References

1. DailyMed official label information from the National Library of Medicine

Eligibility Map: Who can and cannot use Lomax — Official Regulatory Information

The eligibility profile for Lomefloxacin (Lomax) is defined by strict regulatory criteria concerning age, physiological status, and concurrent conditions. Systemic use is contraindicated for several specific populations.

---

Classification	Population/Condition
Absolutely Contraindicated	Hypersensitivity to Lomefloxacin or any quinolone/fluoroquinolone antibacterial agent.
	Pediatric patients (children and adolescents) under 18 years of age for systemic (oral tablet) use.
	Patients with a history of tendon disorders related to previous quinolone use.
Not Recommended/Restricted	Pregnant or breastfeeding women.
	Patients with severely impaired renal function (ClCr le 40 mL/min) without dose adjustment.
	Patients with known prolonged QT interval or those receiving certain antiarrhythmics.
	Patients at higher risk for tendon injury (e.g., older adults, those on corticosteroids).

---

Age-Related Eligibility

• Adults (ge 18 years): Permitted for systemic use with normal renal function.
• Older Adults: Permitted, but require special caution and monitoring of renal function.
• Infants (Ophthalmic Use): Safety and effectiveness have not been established in pediatric patients under one year of age.

Connection to the overall eligibility profile: Official regulatory documents strictly define eligibility by prohibiting use in specific populations with known risks, particularly children and those with quinolone hypersensitivity. For other groups, such as those with impaired renal function, eligibility is conditional, requiring special regulatory dose modifications or cautions.

Interactions with other medicines and products

Lomax's interaction profile is structured around two primary categories: significant reduction in absorption and specific pharmacodynamic risks.

---

Absorption-Interfering Substances (Chelation)

Co-administration with products containing multivalent cations severely reduces the absorption and subsequent systemic concentration of Lomefloxacin. This pharmacokinetic interaction is observed with:

• Antacids that contain aluminum or magnesium, which can reduce the drug's plasma level by one-half.
• Sucralfate, which significantly decreases the drug's bioavailability.
• Iron and Zinc supplements, including multivitamin formulations.

To prevent this reduction, a mandatory separation of administration is required: the cation-containing product must be taken at least 2 to 4 hours apart from the Lomefloxacin dose.

---

Pharmacodynamic and Systemic Effects

The official profile identifies specific combinations that may enhance systemic effects:

• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may increase the potential for the neuroexcitatory activities associated with quinolones.
• QTc-Prolonging Agents (e.g., Class IA and Class III antiarrhythmics) heighten the risk of QT interval prolongation.
• Corticosteroids increase the risk of tendon damage.

In contrast, clinical studies document no significant effect on the disposition parameters or clearance of Theophylline or Caffeine when Lomefloxacin is co-administered.

---

Population-Specific Exposure Note

In patients with severe renal impairment, the clearance of Lomefloxacin is significantly reduced, resulting in a substantially increased systemic exposure (elimination half-life can increase from 7.5 hours to 26.9 hours). This condition magnifies the potential risk and severity of all co-administered drug interactions.

The mechanism of action of Lomax (Lomefloxacin) is defined by its bactericidal role, which involves direct interference with the core genetic machinery of bacterial cells.

Targeted Disruption of Bacterial DNA Enzymes

Lomefloxacin exerts its primary effect by precisely targeting and inhibiting two essential bacterial enzymes: DNA gyrase and Topoisomerase IV. These enzymes are required for managing torsional stress in bacterial DNA during replication and for separating replicated chromosomes. By binding to the DNA-enzyme complex, Lomefloxacin stabilizes a toxic intermediate known as the cleavage complex, thereby halting the enzyme's ability to reseal DNA strands.

Causal Cascade Leading to Cell Death

The failure to reseal DNA strands results in a cascade of lethal double-stranded DNA breaks throughout the bacterial genome. This genetic damage simultaneously and irreversibly halts critical bacterial processes, including DNA replication, transcription, and cell division. This active and systemic failure to repair or replicate leads directly to the destruction of the bacterial cell, which defines the drug's bactericidal physiological effect.

Official Administration Guidelines for Lomax

The usage of Lomax (Lomefloxacin) is defined by its formulations and established parameters which govern its route, dosage, frequency, and relationship with other substances. The medicine is supplied as a 400 mg oral film-coated tablet for systemic treatment and a 0.3% ophthalmic solution for local application to the eye.

Systemic and Local Dosing Patterns

Administration Route	Standard Adult Dose & Frequency	Course Duration Range
Oral Tablet (400 mg)	400 mg taken once daily (qd)	Ranges from a single dose (e.g., prior to transurethral procedures) up to 30 days
Topical Ophthalmic (0.3%)	Typically 1 drop applied 3 times a day	Usually 7 to 9 days

Specific Instructions and Adjustments

Guidelines for the oral tablet's intake include specific parameters. The dose may be taken without regard to meals (with or without food), and intake is typically accompanied by the consumption of plenty of fluids.

Time-Separation Rule: The oral dose is administered at least 4 hours before or 8 hours after ingesting products containing multivalent cations, such as iron, zinc, aluminum, or magnesium (e.g., antacids, sucralfate, or certain mineral supplements).

Dose Adjustment for Impaired Function: The standard dose of 400 mg is not recommended for patients with significant renal impairment. For individuals with a creatinine clearance (CrCl) between 10 and 40 mL/min, the standard maintenance approach involves an initial 400 mg loading dose followed by a reduced maintenance dose of 200 mg once daily. No dose adjustment is recommended for patients with hepatic impairment.

Research Evidence / Overview of Studies for Lomax

Evidence for Use in Acute Urinary Tract Infections (UTI)

The research landscape for Lomefloxacin includes short-term, comparative Randomized Controlled Trials (RCTs) that have explored its use in treating acute bladder infections (uncomplicated UTI) and related complicated infections. These studies, primarily conducted in adult women, research examined two key areas: the measurement of symptom axes (clinical outcomes) and the observation of pathogen absence from the urinary tract (microbiological outcomes).

Studies were designed to assess microbiological outcomes relative to older antibacterial agents. Reports described patterns observed in the studies related to the rates of microbiological clearance (pathogen absence) observed in the short term. The evidence base for uncomplicated UTIs is largely characterized by studies conducted over a decade ago. The applicability of the evidence is limited by the age of the studies and the need for new comparative data.

Evidence for Use in Acute Respiratory Flare-Ups (Chronic Bronchitis)

Research examined the oral film-coated tablet formulation of Lomefloxacin in comparative RCTs for patients experiencing acute flare-ups of chronic bronchitis. These studies focused on conditions characterized by fluctuating or episodic manifestations. Study designs monitored outcomes related to physical discomfort, specifically tracking changes in respiratory symptoms such as cough and sputum production. Furthermore, research explored microbiological outcomes (pathogen clearance) in the lower respiratory system.

Findings indicate patterns related to symptom changes measured during the defined study periods, typically 5 to 10 days of treatment. Studies reported how symptoms evolved in the observed populations and were compared against other standard antibacterial agents. Research provides insight into short-term changes, but the long-term outcomes related to disease progression or subsequent exacerbation frequency are not fully established by these studies.

Research Gaps and Areas of Scientific Uncertainty

Sample sizes were modest in some of the subgroup analyses, and the follow-up durations were limited for understanding long-term recurrence patterns. The existing studies provide limited insight into the comparative effectiveness against the newest available antibacterial agents. Evidence quality varies across studies, and certainty remains low in translating older findings directly into current, complex clinical scenarios, especially given evolving bacterial resistance profiles.

Key Studies & References

1. Efficacy of lomefloxacin as compared to norfloxacin in the treatment of uncomplicated urinary tract infections in adults
2. A double-blind study of two dosage regimens of lomefloxacin in bacteriologically proven exacerbations of chronic bronchitis of gram-negative etiology
3. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines (General context for UTI guidelines and limitations)

Common questions about Lomax (FAQ)

---

Q: Can Lomax be taken while also taking allergy medications?

Official product information describes known interactions with medicines that may affect heart rhythm (QTc-prolonging agents) and substances that block absorption (multivalent cations). Official documents do not list common, non-QTc-prolonging allergy medicines as a specific interaction category.

---

Q: Can older adults (seniors) safely take Lomax?

Older adults are permitted to use Lomax. However, official safety warnings indicate that this population has an increased risk for serious adverse reactions, such as tendon injury. The official eligibility map notes that special caution and monitoring of renal function are required for this group.

---

Q: What does the research say about the long-term use of Lomax?

Studies on Lomax have primarily focused on short-term outcomes for treating acute infections. The official evidence base is limited for fully understanding long-term recurrence patterns or outcomes related to disease progression over extended periods.

---

Q: What were the main findings of the clinical trials for Lomax?

Clinical trials examined key outcomes such as symptom changes reported by patients and the absence of the pathogen, known as microbiological clearance. These studies focused on patients with approved indications, including acute urinary tract infections and acute flare-ups of chronic bronchitis.

---

Q: Is dizziness or lightheadedness a common experience with Lomax?

Official documentation reports that dizziness and lightheadedness are common adverse reactions associated with use. This information is noted in the drug’s safety profile.

---

Q: How likely is it to have stomach issues from taking Lomax?

Official documentation lists gastrointestinal side effects such as nausea, diarrhea, and abdominal pain as commonly reported adverse reactions. This is consistent with the drug's overall safety profile.

---

Q: Does Lomax cause fatigue or tiredness?

Official regulatory warnings for the fluoroquinolone class, which includes Lomax, list fatigue as one of the serious and potentially long-lasting side effects that may occur. This is noted as part of the drug's overall safety profile.

---

Q: Is Lomax used for anything other than its main approved condition?

Lomax is approved by regulatory bodies to treat specific bacterial infections, primarily including acute exacerbation of chronic bronchitis and complicated or uncomplicated urinary tract infections (UTI). Regulatory documents prohibit discussion of any uses outside of these specific, approved indications.

---

Q: Is Lomax considered a strong or a mild medicine?

Lomax is chemically classified as a Fluoroquinolone, which is a potent, broad-spectrum anti-infective agent. Official documents describe it as a broad-spectrum anti-infective agent intended for use against certain bacterial infections, which may include serious infections.

---

Q: Is Lomax a controlled substance?

No, Lomax (lomefloxacin) is not classified as a controlled substance under the US Controlled Substances Act (CSA) or similar international classifications.

---

Q: Does Lomax affect sleep patterns?

Official safety warnings for this class of antibiotics list sleep disorders as a serious, potentially long-lasting side effect that may occur in some individuals. This is noted alongside other central nervous system effects.

---

Q: Can Lomax affect blood sugar levels?

Official drug safety information notes that this class of antibiotics has been associated with disturbances in blood sugar levels. These effects can include both high blood sugar and severe low blood sugar, which is also known as hypoglycemia.

---

Q: Can Lomax make someone feel anxious?

Anxiety is specifically listed in regulatory documents as a psychiatric adverse reaction associated with this class of antibiotics. These types of effects have been reported to sometimes occur shortly after the first dose.

---

Q: Is it normal to feel a change in appetite while on Lomax?

While a significant change in appetite is not always listed as a common effect, official reviews of antibiotics in this class mention loss of appetite as a possible gastrointestinal side effect that may be experienced.

---

Q: Does Lomax have a generic equivalent available?

Generic versions containing Lomefloxacin hydrochloride are available, although the original brand name (Maxaquin) has been discontinued.

---

Q: If I feel better, is it okay to stop taking Lomax early?

Official patient information emphasizes that the infection may not fully clear up if the medicine is stopped too soon. The prescribed course duration is defined for the specific medical problem being treated.

---

Q: Is there a risk of dependency or withdrawal when stopping Lomax?

Regulatory-aligned information indicates that no habit-forming tendencies or specific withdrawal symptoms have been formally reported for Lomefloxacin upon discontinuing treatment.

---

Q: Does taking Lomax change the effectiveness of birth control?

Lomax is classified as a broad-spectrum antibiotic. Official guidance from health bodies states that broad-spectrum antibiotics are not generally known to reduce the effectiveness of combined hormonal contraceptives.

How to Store and Dispose of Lomax?

The storage and handling of Lomax (Lomefloxacin) must strictly follow official regulatory guidelines to maintain product quality and safety.

Storage Requirements

Item	Requirement
Temperature	Tablets must be stored below 25 C. Ophthalmic solution between 20 C and 25 C.
Protection	Keep in the original, tightly closed container and protect from excess light and moisture. The solution must not be frozen.
Child Safety	Store the medicine out of the sight and reach of children.

Disposal Instructions

Unused or expired medication should be properly discarded, as mandated by regulatory authorities. The product should not be poured down drains or flushed. Disposal is typically managed through a community drug take-back program or by mixing with an unappealing substance and sealing it for household trash.